Trandolaprilat is an angiotensin-converting enzyme (ACE) inhibitor.[1] It inhibits angiotensin I-induced contraction in isolated rat thoracic aorta (IC50 = 6.9 nM) and potentiates bradykinin-induced contraction in isolated guinea pig ileum with a 50% augmentation concentration (AC50) value of 2.7 nM. Trandolaprilat induces relaxation of norepinephrine- or potassium chloride-precontracted isolated rat thoracic aorta with intact endothelium in a concentration-dependent manner. Trandolaprilat inhibits angiotensin I-induced pressor responses in rats and dogs (ID50s = 9.9 and 7.2 μg/kg, respectively) and potentiates the bradykinin-induced depressor response in rats (ED50 = 5.5 μg/kg).[2]
Reference:
[1]. Sekiguchi, N., Ishii, Y., Fujikura, H., et al. Pharmacological action of (-)-(2S,3aR,7aS)-1-[(S)-N-[(S)-1-carbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolaprilat) in isolated smooth muscle preparations. Gen. Pharmacol. 24(3), 585-590 (1993).
[2]. Brown, N.L., Badel, M.-Y., Benzoni, F., et al. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570). Eur. J. Pharmacol. 148(1), 79-91 (1988).